Long COVID (PASC): Prevention and Risk Reduction: Infection Avoidance, Vaccination Protection, Acute-Phase Therapeutics, and Recovery Protocols
A preventive medicine reference on reducing infection and reinfection risk, the protective effect of vaccination, early antiviral and metformin treatment during acute infection, and managing convalescence.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is a strong and current brief. The four-stage structure is the right way to organize long COVID prevention, the metformin finding is correctly described including the trial it comes from, and the convalescence section covers the point that most general advice misses. The notes below are mostly about certainty and one safety omission.
- Nirmatrelvir with ritonavir has major drug interactions, and that is missing. Ritonavir affects the metabolism of many common medications, including several statins, some blood thinners, certain heart rhythm drugs, some sedatives and some immunosuppressants. A full medication review is a required part of prescribing it, not an optional check, and this matters precisely because the drug is started urgently within a five-day window.
- The antiviral and long COVID claim is stated more confidently than the evidence supports. Large observational cohorts have suggested lower rates of post-acute sequelae after early antiviral treatment, and more rigorous analyses have been mixed, with some finding no effect on long COVID. The acute benefit in higher-risk people is well established; the long COVID benefit should be described as possible rather than demonstrated.
- The vaccination figure deserves its range. Estimates of the reduction in long COVID risk after vaccination vary widely between studies, from modest to around half, and most are observational. The 30 to 50 percent range is a reasonable summary and should be presented as an estimate with real uncertainty. Part of the benefit also runs through reduced acute severity, which is itself a risk factor.
- Microclotting and viral reservoir persistence are presented as the mechanisms being targeted. Both are active hypotheses with supporting evidence and neither is established. This matters beyond precision: the microclot hypothesis is the basis on which apheresis, sometimes called blood washing, is sold privately at high cost, often alongside anticoagulant drugs, without evidence of benefit and with a real risk of serious bleeding.
- The metformin description is accurate and would benefit from its limits. The COVID-OUT finding comes from one randomized trial, in adults with overweight or obesity, and metformin is not approved or recommended for this indication. It is a legitimate conversation to have with a prescribing clinician during an acute infection, which the brief says, and it is not yet standard practice.
- Saline nasal irrigation carries a specific and fatal risk if done wrongly. The brief correctly specifies distilled or boiled-and-cooled water, and the reason should be stated: untreated tap water has caused fatal brain infections with Naegleria. It is also worth saying that there is no evidence nasal irrigation prevents long COVID; it may ease acute symptoms.
- The four-week signal is the best thing in the brief and it needs one addition. Where symptoms persist and exertion reliably causes a delayed crash, structured exercise programmes that increase activity on a fixed schedule can cause harm. Graded exercise therapy was withdrawn from ME/CFS guidance for this reason. The brief's advice to resume activity gradually over two to four weeks is right for ordinary convalescence and wrong where post-exertional malaise has appeared.
- Red flags during convalescence are missing. Chest pain, sudden or severe breathlessness, fainting, or a swollen painful calf in the weeks after COVID need assessment rather than rest, because blood clots and heart inflammation both occur after infection.
- One framing point. A prevention document is read by people who already have long COVID, and a list of things that would have reduced their risk reads as a list of things they failed to do. Long COVID is not caused by anything a person did or failed to do. People who were vaccinated, masked, treated early and careful in convalescence still develop it, and that should be said plainly.
- Children and young people are not mentioned. They develop long COVID, including after mild infections, and the prevention measures apply to them too.
- Everything else in the brief is accurate: the three-month definition and multisystem presentation; infection avoidance as the only certain prevention; aerosol transmission in poorly ventilated indoor spaces and the role of ventilation, MERV-13 filtration and portable HEPA units; well-fitted N95, KN95 or FFP2 respirators filtering far more than cloth or surgical masks; the cumulative risk of reinfection in observational cohorts; the eligibility criteria and timing windows for nirmatrelvir and remdesivir; the harm of returning to intense exercise too early; the influence of baseline insulin resistance, hypertension, obesity, smoking and sleep apnoea on endothelial vulnerability; and the recommendation to shift to pacing rather than pushing through when symptoms persist past four weeks.
Download the PDF
Our reviewed pages on this
All source documents